Laboratorios Farmaceuticos Rovi, S.A.
LABFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $27 | $25 | $125 | $99 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $144 | $125 | $160 | $130 |
| Inventory | $330 | $338 | $312 | $245 |
| Other Curr. Assets | -$12 | $21 | $26 | $32 |
| Total Curr. Assets | $490 | $509 | $623 | $506 |
| Property Plant & Equip (Net) | $287 | $254 | $216 | $182 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $34 | $28 | $36 | $39 |
| Long-Term Investments | $19 | $1 | $2 | $2 |
| Tax Assets | $2 | $0 | $2 | $4 |
| Other NC Assets | $0 | $9 | $0 | $0 |
| Total NC Assets | $342 | $291 | $256 | $226 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $832 | $800 | $879 | $733 |
| Liabilities | – | – | – | – |
| Payables | $87 | $108 | $126 | $99 |
| Short-Term Debt | $24 | $13 | $13 | $6 |
| Tax Payable | $2 | $5 | $0 | $1 |
| Deferred Revenue | $0 | $0 | $115 | $58 |
| Other Curr. Liab. | $44 | $74 | $155 | $84 |
| Total Curr. Liab. | $157 | $200 | $294 | $190 |
| LT Debt | $91 | $52 | $59 | $67 |
| Deferred Rev, NC | $3 | $3 | $3 | $4 |
| Deferred Tax Liab, NC | $0 | $2 | $1 | $1 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $94 | $57 | $63 | $71 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $16 | $19 | $18 | $18 |
| Total Liabilities | $250 | $256 | $357 | $262 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $3 | $3 | $3 | $3 |
| Retained Earnings | $486 | $556 | $456 | $445 |
| AOCI | $0 | -$0 | $1 | $1 |
| Other Equity | $83 | -$19 | $59 | $22 |
| Total Equity | $572 | $539 | $520 | $471 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $10 | $4 | $1 | $0 |
| Total Liab. & Tot. Equity | $832 | $800 | $879 | $733 |
| Net Debt | $87 | $40 | -$53 | -$26 |